Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis

Experimental Eye Research

Volumn 89, Issue 5, 2009, Pages 700-717

  DeNiro, M ^a,b   Alsmadi, O ^b   Al Mohanna, F ^b  

^a KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

angiogenic factors; diabetic retinopathy; HRMVEC; retinal angiogenesis; YC 1

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; CD31 ANTIGEN; COLLAGEN; ENDOTHELIN 1; ERYTHROPOIETIN; GELATINASE B; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROTEASOME; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; EX VIVO STUDY; EXPLANT; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; REGULATORY MECHANISM; RETINA BLOOD VESSEL; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE; CELL HYPOXIA; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ERYTHROPOIETIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICROVESSELS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEASOME ENDOPEPTIDASE COMPLEX; RETINAL VESSELS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON WILLEBRAND FACTOR;

EID: 70349606004     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2009.06.013     Document Type: Article

References (82)

1. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., and Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118 (1994) 445-450
2. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., John E., Park, Nguyen H.V., Aiello L.M., Ferrara N., and King G. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331 (1994) 1519-1520
3. Ashton N. Retinal vascularization in health and disease. Am. J. Ophthalmol. 44 (1957) 7-17
4. Barinaga M. Shedding light on blindness. Science 267 (1995) 452-453
5. Campochiaro P.A. Retinal and choroidal neovascularization. J. Cell. Physiol. 184 (2000) 301-310
6. Chakrabarti S., and Sima A. Endothelin-1 and endothelin-3-like immunoreactivity in the eyes of diabetic and non-diabetic BB/W rats. Diabetes Res. Clin. Pract. 37 (1997) 109-120
7. Chiang W.C., Teng C.M., Lin S.L., Chen Y.M., Tsai T.J., and Hsieh B.S. YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. Eur. J. Pharmacol. 517 (2005) 1-10
8. Chilov D., Camenisch G., Kvietikova I., Ziegler U., Gassmann M., and Wenger R.H. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1α. J. Cell Sci. 112 (1999) 1203-1212
9. Chun Y.S., Yeo E.J., Choi E., Teng C.M., Bae J.M., Kim M.S., and Park J.W. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem. Pharmacol. 61 (2001) 947-954
10. Chung J.G., Y.J., Huang L.J., Lee F.Y., Teng C.M., Tsai S.C., Lin K.L., Wang S.F., and Kuo S.C. Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics 7 (2007) 3305-3317
11. Cross M.J., Dixelius J., Matsumoto T., and Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28 (2003) 488-494
12. Das A., McLamore A., Song W., and McGuire P.G. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch. Ophthalmol. 117 (1999) 498-503
13. Das A., McGuire P.G., Eriqat C., Ober R.R., DeJuan Jr. E., Williams G.A., McLamore A., Biswas J., and Johnson D.W. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest. Ophthalmol. Vis. Sci. 3 (1999) 809-813
14. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16 (1996) 4604-4613
15. Friebe A., and Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ. Res. 93 (2003) 96-105
16. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C.O., Buerk D.G., Huang P.L., and Jain R.K. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 2604-2609
17. Funasaka T., Yanagawa T., Hogan V., and Raz A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J. 19 (2005) 1422-1430
18. Galbán S., Kuwano Y., Pullmann Jr. R., Martindale J.L., Kim H.H., Lal A., Abdelmohsen K., Yang X., Dang Y., Liu J.O., Lewis S.M., Holcik M., and Gorospe M. RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha, proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol. Cell Biol. 28 (2008) 93-107
19. Gariano R.F., and Gardner T.W. Retinal angiogenesis in development and disease. Nature 438 (2005) 960-966
20. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up regulated by hypoxia. J. Biol. Chem. 272 (1997) 23659-23667
21. Gu Y.Z., Moran S.M., Hogenesch J.B., Wartman L., and Bradfield C.A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3 alpha. Gene Expr. 7 (1998) 205-213
22. Hsiao G., Huang H.Y., Fong T.H., Shen M.Y., Lin C.H., Teng C.M., and Sheu J.R. Inhibitory mechanisms of YC-1 and PMC in the induction of iNOS expression by lipoteichoic acid in RAW 264.7 macrophages. Biochem. Pharmacol. 67 (2004) 1411-1419
23. Hsu H.K., J.S., Ho P.Y., Liang Y.C., Lin C.H., Teng C.M., and Lee W.S. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. Biochem. Pharmacol. 66 (2003) 263-271
24. Hu J., Discher D.J., Bishopric N.H., and Webster K.A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem. Biophys. Res. Commun. 245 (1998) 894-899
25. Huang Y.T., Pan S.L., Guh J.H., Chang Y.L., Lee F.Y., Kuo S.C., and Teng C.M. YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells, suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells. Mol. Cancer Ther. 4 (2005) 1628-1635
26. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., and Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 2863-2867
27. 2 sensing. Science 292 (2001) 464-468
28. 2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
29. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., and Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc. Res. 64 (2002) 326-333
30. Jewell U.R., Kvietikova I., Scheid A., Bauer C., Wenger R.H., and Gassmann M. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 15 (2001) 1312-1314
31. Jing Hu D., Discher D.J., Bishopric N.H., and Webster K.A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem. Biophys. Res. Commun. 245 (1998) 894-899
32. Kelly B.D., Hackett S.F., Hirota K., Oshima Y., Cai Z., Berg-Dixon S., Rowan A., Yan Z., Campochiaro P.A., and Semenza G.L. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 28 (2003) 1074-1081
33. Kelly L.K., Wedgwood S., Steinhorn R.H., and Black S.M. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. Am. J. Physiol. Lung Cell. Mol. Physiol. 5 (2004) L984-L991
34. Kietzmann T., Roth U., and Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood 94 (1999) 4177-4185
35. Kim H.L., Yeo E.J., Chun Y.S., and Park J.W. A domain responsible for HIF-1 alpha degradation by YC-1, a novel anticancer agent. Int. J. Oncol. 29 (2006) 255-260
36. Ko F.N., Wu C.C., Kuo S.C., Lee F.Y., and Teng C.M. YC-1, a novel activator of platelet guanylate cyclase. Blood 84 (1994) 4226-4233
37. Lambert V., Munaut C., Jost M., Noel A., Werb Z., Foidart J.M., and Rakic J.M. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am. J. Pathol. 161 (2002) 1247-1253
38. Lambert V., Wielockx B., Munaut C., et al. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization. FASEB J. 17 (2003) 2290-2292
39. Lau C.K., Yang Z.F., Lam C.T., Tam K.H., Poon R.T., and Fan S.T. Suppression of hypoxia inducible factor-1a (HIF-1a) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem. Biophys. Res. Commun. 4 (2006) 1443-1448
40. Liu Y., Cox S.R., Morita T., and Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 77 (1995) 638-643
41. Liu Y.N., Pan S.L., Peng C.Y., Guh J.H., Huang D.M., Chang Y.L., Lin C.H., Pai H.C., Kuo S.C., Lee F.Y., and Teng C.M. YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9. J. Pharmacol. Exp. Ther. 316 (2006) 35-41
42. Majka S., McGuire P., Colombo S., et al. The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 42 (2001) 210-215
43. Majka S., McGuire P.G., and Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 43 (2002) 260-266
44. Matsumoto T., and Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 112 RE21 (2001) 1-17
45. Michaelson I. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans. Ophthalmol. Soc. U. K. 68 (1948) 137-180
46. Minet E., Michel G., Remacle J., and Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). Int. J. Mol. Med. 3 (2000) 253-259
47. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
48. Ozaki H., Yu A.Y., Della N., Ozaki K., Luna J.D., Yamada H., Hackett S.F., Okamoto N., Zack D.J., Semenza G.L., and Campochiaro P.A. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest. Ophthalmol. Vis. Sci. 40 (1999) 182-189
49. Pan S.L., Guh J.H., Peng C.Y., Chang Y.L., Cheng F.C., Chang J.H., Kuo S.C., Lee F.Y., and Teng C.M. A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb. Haemost. 93 (2005) 940-948
50. Pe'er J., Shweiki D., Itin A., Hemo I., Gnessin H., and Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72 (1995) 638-645
51. Russ P.K., Gaylord G.M., and Haselton F.R. Retinal vascular permeability determined by dual-tracer fluorescence angiography. Ann. Biomed. Eng. 29 (2001) 638-647
52. Sánchez-Elsner T., Botella L.M., Velasco B., Langa C., and Bernabéu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 15 (2002) 43799-43808
53. Sarman S., van der Ploeg I., Seregard S., and Kvanta A. Retinal vascular development and pathologic retinal angiogenesis are not impaired in matrix metalloproteinase-2 deficient mice. Curr. Eye Res. 30 (2005) 259-267
54. Semenza G.L. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem. Pharmacol. 59 (2000) 47-53
55. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13 (2001) 167-171
56. Sheth J.J. Diabetes, microalbuminuria and hypertension. Clin. Exp. Hypertens. 21 (1999) 61-68
57. Shiels I.A., Zhang S., Ambler J., and Taylor S.M. Vascular leakage stimulates phenotype alteration in ocular cells, contributing to the pathology of proliferative vitreoretinopathy. Med. Hypotheses 50 (1998) 113-117
58. Sivak J.M., and Fini M.E. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog. Retin. Eye Res. 21 (2002) 1-14
59. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., and D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35 (1994) 101-111
60. Song S., Chung H., and Yu H.G. Inhibitory effect of YC-1, 3-(5′-hydroxymethyl-2′-furyl)-1 benzylindazole, on experimental choroidal neovascularization in rat. Ophthalmic Res. 40 (2008) 35-40
61. Steen B., Sejersen S., Berglin L., Seregard S., and Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 39 (1998) 2194-2200
62. Stitt A.W., Bhaduri T., McMullen C.B., Gardiner T.A., and Archer D.B. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol. Cell. Biol. Res. Commun. 3 (2000) 380-388
63. Sun H.L., L. Y., Huang Y.T., Pan S.L., Huang D.Y., Guh J.H., Lee F.Y., Kuo S.C., and Teng C.M. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NFkappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 26 (2007) 3941-3951
64. Thieme H., Aiello L.P., Takagi H., Ferrara N., and King G.L. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 44 (1995) 98-103
65. Wall D.S., Gendron R.L., Good W.V., Miskiewicz E., Woodland M., Leblanc K., and Paradis H. Conditional knockdown of tubedown-1 in endothelial cells leads to neovascular retinopathy. Invest. Ophthalmol. Vis. Sci. 45 (2004) 3704-3712
66. Wang G.L., and Semenza G. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 15 (1993) 3610-3615
67. 2 tension. Proc. Natl. Acad. Sci. U.S.A. 6 (1995) 5510-5514
68. Wang G.L., and Semenza G. Molecular basis of hypoxia-induced erythropoietin expression. Curr. Opin. Hematol. 3 (1996) 156-162
69. Wang G.Y., Ji B., Wang X., and Gu J.H. Anti-cancer effect of iNOS inhibitor and its correlation with angiogenesis in gastric cancer. World J. Gastroenterol. 11 (2005) 3830-3833
70. Wang G.Y., Gu J.H., Lu G.Y., and Meng X.Y. Effects of aminoguanidine on transplantation stomach cancer in mice. J. Jilin Univ. 30 (2004) 409-412
71. Wang G.Y., and Wang X. Relationship between tumor angiogenesis and expression of vascular endothelial growth factor and nitric oxide synthase in human gastric cancer. Zhongguo Puwai Jichu Yu Linchuang Zazhi 11 (2004) 55-57
72. 1 in human hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 312 (2005) 917-925
73. Wang X., and Wang G.Y. Expression of vascular endothelial growth factor and nitric oxide synthase in human gastric cancer and its relation to angiogenesis and clinical pathology. Zhonghua Weichang Waike Zazhi 5 (2002) 145-148
74. Wang Y., Hui Y., Guo B., Hou X., and Ma J. Inhibition of retinal microvascular endothelial cells migration and tube formation by pericytes through down-regulating Flk-1 mRNA. J. US-China Med. Sci. 3 (2006) 5-13
75. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M., Suzuma I., Ohashi H., Ojima T., Murakami T., Kobayashi T., Masuda S., Nagao M., Yoshimura N., and Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353 (2005) 782-792
76. Wenger R.H. Mammalian oxygen sensing, signaling and gene regulation. J. Exp. Biol. 203 (2000) 1253-1263
77. Williamson J.R., Chang K., and Frangos M. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42 (1993) 801-813
78. Wouters A., Pauwels B., Vermorken J.B., and Lardon F. Hypoxia inducible factor 1 (HIF-1) and tumour biology. Bel. J. Med. Oncol. 2 (2008) 3-8
79. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., and Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
80. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., and Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88 (2000) 2606-2618
81. Zhang X., Sakamoto T., Hata Y., et al. Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats. Exp. Eye Res. 74 (2002) 577-584
82. Zhao Q., Du J., Gu H., Teng X., Zhang Q., Qin H., and Liu N. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 34 (2007) 242-247